Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial

INTRODUCTION: The recent CONCEPT study showed that 800 mg/day of pharmaceutical-grade chondroitin sulfate (CS) was superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in patients with symptomatic knee osteoarthritis (OA). We investigate, in the present...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruyère, Olivier, Dardenne, Nadia, Donneau, Anne-Françoise, Reginster, Jean-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547984/
https://www.ncbi.nlm.nih.gov/pubmed/32954487
http://dx.doi.org/10.1007/s12325-020-01484-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547984/
https://www.ncbi.nlm.nih.gov/pubmed/32954487
http://dx.doi.org/10.1007/s12325-020-01484-x

Ejemplares similares